Research programme: biotherapeutics - Eli Lilly/GlycoFi
Latest Information Update: 14 Apr 2009
At a glance
- Originator Eli Lilly; GlycoFi
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 03 Nov 2005 Preclinical trials in Undefined in USA (unspecified route)